WO2003012080A3 - Ex-vivo selection of t-cells with reduced alloreactivity and use thereof in bone marrow transplantations - Google Patents

Ex-vivo selection of t-cells with reduced alloreactivity and use thereof in bone marrow transplantations Download PDF

Info

Publication number
WO2003012080A3
WO2003012080A3 PCT/EP2002/008052 EP0208052W WO03012080A3 WO 2003012080 A3 WO2003012080 A3 WO 2003012080A3 EP 0208052 W EP0208052 W EP 0208052W WO 03012080 A3 WO03012080 A3 WO 03012080A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
bone marrow
vivo selection
marrow transplantations
reduced alloreactivity
Prior art date
Application number
PCT/EP2002/008052
Other languages
German (de)
French (fr)
Other versions
WO2003012080A2 (en
Inventor
Ahmed Sheriff
Original Assignee
Genethor Gmbh
Ahmed Sheriff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10135615A external-priority patent/DE10135615A1/en
Priority claimed from EP01121806A external-priority patent/EP1291414A1/en
Application filed by Genethor Gmbh, Ahmed Sheriff filed Critical Genethor Gmbh
Priority to AU2002321240A priority Critical patent/AU2002321240A1/en
Publication of WO2003012080A2 publication Critical patent/WO2003012080A2/en
Publication of WO2003012080A3 publication Critical patent/WO2003012080A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to a reduction of allologous immune reactions. In said method the regulatory properties of antigen-presenting cells are used to eliminate ex-vivo graft vs host reactions.
PCT/EP2002/008052 2001-07-21 2002-07-19 Ex-vivo selection of t-cells with reduced alloreactivity and use thereof in bone marrow transplantations WO2003012080A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002321240A AU2002321240A1 (en) 2001-07-21 2002-07-19 Ex-vivo selection of t-cells with reduced alloreactivity and use thereof in bone marrow transplantations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10135615A DE10135615A1 (en) 2001-07-21 2001-07-21 Treatment of antigen-presenting cells or their precursors, useful e.g. in treatment of leukemia, by suppressing allologous immune responses to tissue grafts
DE10135615.3 2001-07-21
EP01121806.2 2001-09-11
EP01121806A EP1291414A1 (en) 2001-09-11 2001-09-11 Ex vivo selection of T-cells with reduced alloreactivtiy (diminshed graft-versus-host effect and enhanced graft-verus-leukemia effect) and use therof in bone marrow transplantations

Publications (2)

Publication Number Publication Date
WO2003012080A2 WO2003012080A2 (en) 2003-02-13
WO2003012080A3 true WO2003012080A3 (en) 2003-08-28

Family

ID=26009749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008052 WO2003012080A2 (en) 2001-07-21 2002-07-19 Ex-vivo selection of t-cells with reduced alloreactivity and use thereof in bone marrow transplantations

Country Status (2)

Country Link
AU (1) AU2002321240A1 (en)
WO (1) WO2003012080A2 (en)

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
APPELBAUM FREDERICK R: "Haematopoietic cell transplantation as immunotheraphy.", NATURE (LONDON), vol. 411, no. 6835, 2001, pages 385 - 389, XP002187722, ISSN: 0028-0836 *
APPLEMAN LEONARD J ET AL: "Helper T cell anergy: From biochemistry to cancer pathophysiology and therapeutics.", JOURNAL OF MOLECULAR MEDICINE (BERLIN), vol. 78, no. 12, 2001, pages 673 - 683, XP002187721, ISSN: 0946-2716 *
BLAZAR BRUCE R ET AL: "CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses.", JOURNAL OF CLINICAL INVESTIGATION, vol. 102, no. 3, 1 August 1998 (1998-08-01), pages 473 - 482, XP002187718, ISSN: 0021-9738 *
CHAMPLIN RICHARD ET AL: "Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 111, no. 1, October 2000 (2000-10-01), pages 18 - 29, XP002187720, ISSN: 0007-1048 *
GUINAN EVA C ET AL: "Transplantation of anergic histoincompatible bone marrow allografts.", NEW ENGLAND JOURNAL OF MEDICINE, vol. 340, no. 22, 9 June 1999 (1999-06-09), pages 1704 - 1714, XP002187717, ISSN: 0028-4793 *
LU L ET AL: "ADENOVIRAL DELIVERY OF CTLA4LG INTO MYELOID DENDRITIC CELLS PROMOTES THEIR IN VITRO TOLEROGENICITY AND SURVIVAL IN ALLOGENEIC RECIPIENTS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 4, 1999, pages 554 - 563, XP000946114, ISSN: 0969-7128 *
ZELLER ET AL: "Induction of CD4+ T Cell Alloanitgen-Specific Hyporesponsiveness by Il-10 and TGF-beta", THE JOURNAL OF IMMUNOLOGY, vol. 163, 1999, pages 3684 - 3691, XP002187719 *

Also Published As

Publication number Publication date
AU2002321240A1 (en) 2003-02-17
WO2003012080A2 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
AU2002339710A1 (en) Biological vessel suspending assembly and method
AU9102898A (en) Pluripotential bone marrow cell line and methods of using the same
EP1273312A3 (en) Implant for cartilage tissue regeneration
AU2002320456A1 (en) Removable stent and method of using the same
WO2004002424A8 (en) Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
AU2002314790A1 (en) Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
AU2002322211A1 (en) Methods and compisitions for activation human t cells in vitro
AU2002316448A1 (en) Method of promoting engraftment of a donor transplant in a recipient host
AU3691797A (en) Double-stranded dna with cohesive end(s), and method of shuffling dna using the same
AU2003222149A1 (en) High level expression of immunogenic proteins in the plastids of higher plants
AU2002234861A1 (en) Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation
AU2002306766A1 (en) Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
WO2001032840A3 (en) Hair transplantation
AU2002336658A1 (en) Il-4 mutein proteins, antibodies, compositions, methods and uses
WO2000029551A3 (en) Cells, culture methods, and their use in autologous transplantation therapy
AU1705599A (en) Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
AU2003287521A1 (en) Pluripotent cells from monocytes, and methods of making and using pluripotent cells
WO2005017115A3 (en) Cord blood-derived hematopoietic progenitor cells
WO2003012080A3 (en) Ex-vivo selection of t-cells with reduced alloreactivity and use thereof in bone marrow transplantations
AU2003281309A1 (en) Novel undifferentiated stem cells contained in cord blood, bone marrow, peripheral blood or the like
WO2003029432A3 (en) Human mesenchymal progenitor cell
AU2001252591A1 (en) Novel promoters and gene expression method by using the promoters
AU2002246585A1 (en) Plant promoters, and methods of use
AU2001277742A1 (en) Solid culture medium and method for preparing the same
AU3623699A (en) Controlled power splitting and combining transmission (cpsct)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP